Literature DB >> 32806946

Incidence and Hematological Biomarkers Associated With Preoperative Deep Venous Thrombosis Following Foot Fractures.

Jiangtao Ma1,2, Jin Qin1,2, Jinglve Hu1,2, Meishuang Shang1,2, Yali Zhou1,2, Ningxi Liang1,2, Yingze Zhang3,4, Yanbin Zhu3,5.   

Abstract

BACKGROUND: This study was designed to investigate the incidence and hematological biomarker levels that are associated with deep venous thrombosis (DVT) following closed foot fractures (except calcaneal fractures).
METHODS: A retrospective analysis of data on patients presenting with closed foot fractures (excluding the calcaneus) between October 2014 and December 2018 was conducted. Duplex ultrasonography was used to screen preoperative DVT of bilateral lower extremities. Data on demographics, comorbidities, types of fracture, and laboratory biomarkers at admission were collected. Univariate analyses and multivariate logistic regression analyses were carried out to determine the independent risk factors associated with DVT.
RESULTS: A total of 537 patients were included, among whom 28 patients had preoperative DVTs, indicating a crude incidence rate of 5.2%. In isolated closed foot fractures, DVT occurred in 12 (2.9%) out of 410 patients, while in patients with concurrent fracture in other locations, 16 (12.6%) out of 127 patients developed DVT. The average interval between fracture occurrence and diagnosis of DVT was 4.2 days (median, 2 days), ranging from 0 to 17 days. Twenty-four patients (85.7%) developed DVT in the injured extremity, 3 (10.7%) in the uninjured extremity, and 1 (3.5%) in bilateral extremities. Seven risk factors were identified to be associated with DVT, including alcohol consumption, concomitant other fractures, platelet distribution width (PDW) <12%, high-density lipoprotein cholesterol (HDL-C) <1.1mmol/L, serum alkaline phosphatase (ALP) >100 U/L, serum sodium concentration (Na+) <135 mmol/L, and D-dimer >0.5 mg/L.
CONCLUSION: Being aware of the prevalence of DVT in closed foot fractures can help physicians to carry out the overall assessment, risk stratification, and individual prevention programs. LEVEL OF EVIDENCE: Level III, a prospective cohort study.

Entities:  

Keywords:  closed foot fractures; deep venous thrombosis; risk factors

Mesh:

Substances:

Year:  2020        PMID: 32806946     DOI: 10.1177/1071100720943844

Source DB:  PubMed          Journal:  Foot Ankle Int        ISSN: 1071-1007            Impact factor:   2.827


  5 in total

1.  Surgeon volume and the risk of deep surgical site infection following open reduction and internal fixation of closed tibial plateau fracture.

Authors:  Yanbin Zhu; Shiji Qin; Yuxuan Jia; Junyong Li; Wei Chen; Qi Zhang; Yingze Zhang
Journal:  Int Orthop       Date:  2021-09-22       Impact factor: 3.075

2.  Relationship between surgeon volume and the risk of deep surgical site infection (DSSI) following open reduction and internal fixation of displaced intra-articular calcaneal fracture.

Authors:  Shiji Qin; Yanbin Zhu; Hongyu Meng; Junzhe Zhang; Junyong Li; Kuo Zhao; Yingze Zhang; Wei Chen
Journal:  Int Wound J       Date:  2021-10-15       Impact factor: 3.099

Review 3.  Characteristics of Deep Venous Thrombosis in Isolated Lower Extremity Fractures and Unsolved Problems in Guidelines: A Review of Recent Literature.

Authors:  Wei-Guang Zhao; Wei-Li Zhang; Ying-Ze Zhang
Journal:  Orthop Surg       Date:  2022-05-27       Impact factor: 2.279

4.  Red Cell Distribution Width-to-High-Density Lipoprotein Cholesterol Ratio (RHR): A Promising Novel Predictor for Preoperative Deep Vein Thrombosis in Geriatric Patients with Hip Fracture.

Authors:  Xinqun Cheng; Lingjia Fan; Jiabei Hao; Honghou He; Jincheng Yan; Yanbin Zhu
Journal:  Clin Interv Aging       Date:  2022-09-01       Impact factor: 3.829

5.  The incidence and risk factors of deep venous thrombosis in lower extremities following surgically treated femoral shaft fracture: a retrospective case-control study.

Authors:  Zhixin Ren; Yufei Yuan; Wei Qi; Yanbao Li; Pengcheng Wang
Journal:  J Orthop Surg Res       Date:  2021-07-09       Impact factor: 2.359

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.